10.20

3.23% -0.34

Ocular Therapeutix Inc (OCUL)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché OCUL Giù? Forum Previsione

Precedente Chiudi:

$10.54

Aprire:

$10.51

Volume 24 ore:

1.88M

Relative Volume:

0.63

Capitalizzazione di mercato:

$2.23B

Reddito:

$52.04M

Utile/perdita netta:

$-290.50M

Rapporto P/E:

-7.0069

EPS:

-1.4557

Flusso di cassa netto:

$-240.94M

1 W Prestazione:

+5.81%

1M Prestazione:

+16.70%

6M Prestazione:

-9.41%

1 anno Prestazione:

-7.94%

Intervallo 1D:

$10.06

$10.53

Intervallo di 1 settimana:

$9.425

$10.94

Portata 52W:

$6.2301

$16.44

Ocular Therapeutix Inc Stock (OCUL) Company Profile

Nome

Ocular Therapeutix Inc

Settore

Healthcare (1096)

Industria

Biotechnology (616)

Telefono

781-357-4000

Indirizzo

14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA

Dipendente

325

Cinguettio

@OCUTX

Prossima data di guadagno

2026-08-04

Ultimi documenti SEC

OCUL's Discussions on Twitter

Compare OCUL vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
OCUL Ocular Therapeutix Inc	10.20	2.23B	52.04M	-290.50M	-240.94M	-1.4557
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-09-15	Iniziato	Chardan Capital Markets	Buy
2025-04-08	Iniziato	William Blair	Outperform
2025-03-18	Iniziato	RBC Capital Mkts	Outperform
2025-03-11	Iniziato	Needham	Buy
2024-10-16	Iniziato	Scotiabank	Sector Outperform
2024-06-20	Aggiornamento	TD Cowen	Hold → Buy
2024-05-31	Ripresa	Piper Sandler	Overweight
2024-02-09	Iniziato	BofA Securities	Buy
2023-04-21	Iniziato	Robert W. Baird	Outperform
2022-08-10	Ripresa	Berenberg	Buy
2021-08-10	Aggiornamento	H.C. Wainwright	Neutral → Buy
2020-12-28	Downgrade	H.C. Wainwright	Buy → Neutral
2020-12-17	Iniziato	Berenberg	Buy
2020-11-13	Reiterato	Raymond James	Strong Buy
2020-08-10	Reiterato	H.C. Wainwright	Buy
2020-03-03	Aggiornamento	Raymond James	Outperform → Strong Buy
2019-05-21	Downgrade	Cowen	Outperform → Market Perform
2019-05-21	Reiterato	H.C. Wainwright	Buy
2019-05-21	Downgrade	Raymond James	Strong Buy → Outperform
2018-12-03	Reiterato	Cantor Fitzgerald	Overweight
2018-11-15	Iniziato	Raymond James	Strong Buy
2018-09-07	Iniziato	Piper Jaffray	Overweight
2017-10-24	Iniziato	Guggenheim	Buy
2017-07-26	Iniziato	H.C. Wainwright	Buy
2017-07-12	Reiterato	Cantor Fitzgerald	Overweight
2017-06-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2017-02-10	Iniziato	Cantor Fitzgerald	Overweight
2016-11-15	Reiterato	RBC Capital Mkts	Outperform
2016-08-11	Iniziato	JMP Securities	Mkt Outperform
2016-02-17	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2015-10-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2015-08-13	Iniziato	Morgan Stanley	Overweight

Mostra tutto

Ocular Therapeutix Inc Borsa (OCUL) Ultime notizie

Jul 11, 2026

(OCUL) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Jul 11, 2026

Jul 10, 2026

Does Ocular Therapeutix (OCUL) Joining Russell Value Indexes Quietly Recast Its Long‑Term Investor Base? - simplywall.st

Jul 10, 2026

Jul 09, 2026

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jul 09, 2026

FDA approves Dextenza for third indication: Ocular itching from allergic conjunctivitis - Ophthalmology Times Europe

Jul 09, 2026

Jul 08, 2026

Ocular Therapeutix (OCUL) Joins Russell Value Indexes, Is The Stock Now Too Pricey? - Sahm

Jul 08, 2026

Jul 06, 2026

Ocular Therapeutix (OCUL) Holds Steady Near Key Support Levels Amid Low VolumeOn Balance Volume - dars.gov.et

Jul 06, 2026

Ocular Therapeutix options trading jumps to 9,894 contracts By Investing.com - Investing.com Canada

Jul 06, 2026

Price to earnings forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL - TradingView

Jul 04, 2026

Jul 03, 2026

Ocular Therapeutix Inc to Host Investor Day Transcript - GuruFocus

Jul 03, 2026

Enterprise value to revenue forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL - TradingView

Jul 03, 2026

Price to sales forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL - TradingView

Jul 03, 2026

Price to book forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL - TradingView

Jul 03, 2026

Enterprise value to EBIT forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL - TradingView

Jul 03, 2026

Enterprise value to EBITDA forward of Ocular Therapeutix, Inc. – NASDAQ:OCUL - TradingView

Jul 03, 2026

Jul 01, 2026

Ocular Therapeutix to present new retinal disea... - Pluang

Jul 01, 2026

Does Broad Russell Value Index Inclusion Reshape the Bull Case for Ocular Therapeutix (OCUL)? - simplywall.st

Jul 01, 2026

Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences - GlobeNewswire

Jul 01, 2026

Jun 30, 2026

(OCUL) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Jun 30, 2026

Jun 29, 2026

Ocular Therapeutix, Inc.(NasdaqGM: OCUL) added to Russell 2000 Value Benchmark - marketscreener.com

Jun 29, 2026

Ocular Therapeutix (OCUL) Could Be 62% Below Fair Value After Axpaxli FDA Feedback - Sahm

Jun 29, 2026

Jun 28, 2026

Ocular Therapeutix, Inc.(NasdaqGM: OCUL) added to Russell 2500 Value Benchmark - marketscreener.com

Jun 28, 2026

Ocular Therapeutix, Inc.(NasdaqGM:OCUL) added to Russell Small Cap Comp Value Benchmark - marketscreener.com

Jun 28, 2026

Jun 27, 2026

OCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda? - Stocktwits

Jun 27, 2026

Jun 26, 2026

OCUL Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Ocular Therapeutix Inc Actuals & Estimates (BX:0OT) - TradingView

Jun 26, 2026

Ocular Therapeutix Inc Actuals & Estimates (HAM:0OT) - TradingView

Jun 26, 2026

Jun 25, 2026

Chardan Capital Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Raises Target Price to $23 - Moomoo

Jun 25, 2026

OCUL Maintained by Chardan Capital -- Price Target Raised to $23 - GuruFocus

Jun 25, 2026

Is Ocular Therapeuticx, Inc. (OCUL) Stock Positioned for Growth After Positive FDA Feedback on Axpaxli? - Yahoo Finance

Jun 25, 2026

Jun 24, 2026

5 Best Healthcare Stocks to Buy According to Wall Street Analysts - Insider Monkey

Jun 24, 2026

Ocular Therapeutix (OCUL): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance

Jun 24, 2026

Jun 22, 2026

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo

Jun 22, 2026

BofA Securities Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $27 - Moomoo

Jun 22, 2026

H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $25 - Moomoo

Jun 22, 2026

H.C. Wainwright raises Ocular Therapeutix price target to $25 on FDA pathway clarity - Investing.com Nigeria

Jun 22, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jun 22, 2026

Jun 19, 2026

OCUL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Jun 19, 2026

Analysts Are Bullish on These Healthcare Stocks: Prime Medicine, Inc. (PRME), Ocular Therapeutix (OCUL) - The Globe and Mail

Jun 19, 2026